Baicalin affects dopamine homeostasis in the ADHD model by regulating the balance between DAT and VMAT2 transport via the activation of Nrf2/Keap-1/HO-1 signaling pathway

Free Radical Biology and Medicine, Год журнала: 2025, Номер unknown

Опубликована: Фев. 1, 2025

Язык: Английский

---

Aniracetam Ameliorates Attention Deficit Hyperactivity Disorder Behavior in Adolescent Mice

eNeuro, Год журнала: 2025, Номер 12(3), С. ENEURO.0578 - 24.2025

Опубликована: Март 1, 2025

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental that affects 8–12% of children globally. Hyperactivity-related behaviors, as well inattention and impulsivity, are regarded the nuclear symptoms ADHD. At present, its etiologies risk factors unknown. Previous research linked TARP γ-8 deficiency to ADHD-like behaviors in mice, including hyperactivity, memory deficits. Aniracetam, nootropic drug, enhances cognition by modulating cholinergic activity glutamate receptors, offering neuroprotective effects. This study examined knockout (KO) mice at 4 8 weeks, assessing through locomotor activity, cliff avoidance, novel object recognition, contextual fear conditioning tests. KO exhibited reduced recognition memory, impaired short-term long-term memory. Aniracetam administration improved these behavioral deficits, suggesting potential therapeutic agent for The findings align with ADHD’s pathophysiology, resembling neurological impairments mice. shows promise treatment ADHD symptoms, highlighting value.

Язык: Английский

---

Astaxanthin Mitigates ADHD Symptoms in Spontaneously Hypertensive Rats via Dopaminergic Modulation and Brain–Gut Axis Regulation

Molecules, Год журнала: 2025, Номер 30(7), С. 1637 - 1637

Опубликована: Апрель 7, 2025

Attention Deficit Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental disorder that significantly impacts learning, daily functioning, and personal development. Astaxanthin (ASTA), naturally occurring antioxidant, has garnered interest as potential therapeutic agent for various diseases, particularly in mitigating oxidative stress. This study explores novel application of ASTA the context ADHD, aiming to investigate its effects underlying mechanisms. Spontaneously hypertensive rats (SHRs), widely used ADHD model animals, were treated with (50/100 mg/kg/day) three weeks, 5 mg/kg/day atomoxetine (ATO) positive, Wistar Kyoto (WKY) control. Behavioral improvements assessed using open field test (OFT) Morris water maze (MWM). Biochemical analyses conducted evaluate changes levels neurotrophic factors, while histological examinations performed assess neuroprotective effects. Additionally, role brain–gut axis was investigated. The behavioral symptoms hyperactivity, anxiety, impaired spatial memory animals mitigated by ASTA. improvement primarily attributed restoration neurotransmitter levels, dopamine (DA), achieved through modulation several critical components within system, including receptor 1 (DR1), transporter (DAT), tyrosine hydroxylase (TH), synaptic-associated protein 25 (SNAP-25). regulating serotonin (SERT) glial cell-derived factor (GDNF) supports recovery facilitates optimal brain Furthermore, cerebellar cells protected, structure intestinal microbiota regulated. can mitigate SHR dopaminergic multiple neurotransmitters, neuro-intestinal environment, which establishes promising nutraceutical candidate adjunctive therapy pediatric ADHD.

Язык: Английский

---

GFOD1 regulates oxidative stress-induced damage in ADHD via NF-κB signaling pathway

Brain Research, Год журнала: 2025, Номер unknown, С. 149605 - 149605

Опубликована: Апрель 1, 2025

Язык: Английский

---

Exploring the shared genetic basis of attention-deficit/hyperactivity disorder and obstructive sleep apnea: A multi-omics analysis

Progress in Neuro-Psychopharmacology and Biological Psychiatry, Год журнала: 2025, Номер unknown, С. 111369 - 111369

Опубликована: Апрель 1, 2025

Язык: Английский

---